Please login to the form below

Not currently logged in
Email:
Password:

GSK cuts HIV drug prices

GlaxoSmithKline has announced that it is cutting the prices of drugs and treatments used to combat HIV in third world countries.

GlaxoSmithKline (GSK) has announced that it is cutting the prices of drugs and treatments used to combat HIV in third world countries.

Ziagen, which the World Health Organisation (WHO) considers a first and second line regimen, will receive a 40 percent price reduction.

GSK has made significant improvement to manufacturing efficiency that has enabled them to cut the costs of drugs essential in combating the devastating effects of HIV.

CEO of GSK, JP Garnier, said: "This further reduction in pricing of our HIV medicines demonstrates GSK's ongoing commitment to patients in the world's poorest countries."

On average, prices for GSK's 14 specified not-for-profit antiretrovirals will immediately go down by 21 percent, and the savings will be passed onto public sector and developing nation customers.

Garnier said: "I have seen for myself the devastating impact of HIV/AIDS, and the continued response of the global community to this epidemic is vital."

In 2001 GSK became a founding member of the Accelerating Access Initiative (AAI), which was created to ensure greater intervention in the fight against HIV/Aids.

Finance minister for South Africa, Trevor Manuel, has also pledged his nations continued support by promising to spend an extra $269.4 million on HIV/Aids prevention over the next three years.

20th February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics